abstract |
The present invention provides a Relaxin fusion polypeptide having an extended half-life. Among them, the half-life extension is partly the Fc portion of human IgG2 or human IgG4. Furthermore, the present invention provides a nucleic acid sequence encoding the aforementioned fusion polypeptide, a vector containing the same, a pharmaceutical composition, and a medical use of the fusion polypeptide. |